Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease : Subgroup Analysis of DIAMOND Randomized Trial
Weir, Matthew R. (University of Maryland School of Medicine)
Rossignol, Patrick (Centre d'Hémodialyse Privé de Monaco)
Pitt, Bertram (University of Michigan)
Lund, Lars H. (Karolinska University Hospital)
Coats, Andrew J. S. (Heart Research Institute)
Filippatos, Gerasimos (University General Hospital Attikon (Haidari, Grècia))
Perrin, Amandine (CSL Vifor)
Waechter, Sandra (CSL Vifor)
Budden, Jeffrey (CSL Vifor)
Kosiborod, Mikhail (University of Missouri-Kansas City)
Metra, Marco (ASST Spedali Civili and University (Brescia, Itàlia))
Boehm, Michael (Saarland University)
Ezekowitz, Justin A. (University of Alberta (Canadà))
Bayés-Genís, Antoni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Mentz, Robert J. (Department of Medicine, Duke University School of Medicine)
Ponikowski, Piotr (Institute of Heart Diseases, Wroclaw Medical University)
Senni, Michele (University of Milano-Bicocca (Itàlia))
Castro-Montes, Eliodoro (Universidad Autónoma de Querétaro (Mèxic))
Nicolau, Jose Carlos (Universidade de São Paulo)
Parkhomenko, Alexandr (Institute of Cardiology, Clinical and Regenerative Medicine)
Seferovic, Petar (University of Belgrade)
Cohen-Solal, Alain (Université de Paris)
Anker, Stefan D. (German Heart Center Charité)
Butler, Javed (University of Michigan)
Universitat Autònoma de Barcelona

Data:	2024
Resum:	Renin-angiotensin-aldosterone system inhibitor (RAASi; including mineralocorticoid receptor antagonists [MRAs]) benefits are greatest in patients with heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD); however, the risk of hyperkalemia (HK) is high. The DIAMOND trial (NCT03888066) assessed the ability of patiromer to control serum potassium (sK +) in patients with HFrEF with/without CKD. Prior to randomization (double-blind withdrawal, 1:1), patients on patiromer had to achieve ≥50% recommended doses of RAASi and 50 mg/day of MRA with normokalemia during a run-in period. The present analysis assessed the effect of baseline estimated glomerular filtration rate (eGFR) in subgroups of ≥/<60, ≥/<45 (prespecified), and ≥/<30 mL/min/1. 73 m 2 (added post hoc). In total, 81. 3, 78. 9, and 81. 1% of patients with eGFR <60, <45, and <30 mL/min/1. 73 m 2 at screening achieved RAASi/MRA targets. A greater efficacy of patiromer versus placebo to control sK + in patients with more advanced CKD was reported (p - ≤ 0. 027 for all eGFR subgroups). Greater effects on secondary endpoints were observed with patiromer versus placebo in patients with eGFR <60 and <45 mL/min/1. 73 m 2. Adverse effects were similar between patiromer and placebo across subgroups. Patiromer enabled use of RAASi, controlled sK +, and minimized HK risk in patients with HFrEF, with greater effect sizes for most endpoints noted in patient subgroups with lower eGFR. Patiromer was well tolerated by patients in all eGFR subgroups. Patients with chronic kidney disease (CKD) can develop high potassium (hyperkalemia) levels in their blood that can lead to complications such as heart issues. Renin-angiotensin-aldosterone system inhibitors (RAASis) are used as treatment for heart failure and CKD, but can also cause hyperkalemia, so are underutilized and used at lower than optimal doses. Patiromer is a potassium binder which was investigated in the DIAMOND trial to identify if it could reduce hyperkalemia in patients receiving RAASis. Lower kidney function (eGFR) has been associated with a greater likelihood of stopping treatment with RAASis; therefore, this analysis assessed the effect of patiromer on patients with varying eGFR levels. Patiromer enabled use of effective RAASi doses, controlled the serum potassium levels and minimized hyperkalemia in patients with heart failure and CKD.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	DIAMOND trial ; Chronic kidney disease ; Mineralocorticoid receptor antagonist ; Adverse effects ; Adverse events ; Hyperkalemia ; Renin-angiotensin-aldosterone system inhibitors (RAASis)
Publicat a:	American Journal of Nephrology, Vol. 55 (august 2024) , p. 672-689, ISSN 1421-9670

DOI: 10.1159/000540453
PMID: 39159624

18 p, 1.4 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats